Pilaralisib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	13	—	—	2007-06
Malignant Breast Neoplasm	Phase2	Phase 2	3	—	—	2008-06
Malignant Uterine Corpus Neoplasm	Phase2	Phase 2	2	—	—	2008-09
Malignant Central Nervous System Neoplasm	Phase1	Phase 1	1

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Amplification1
Pilaralisib + Trastuzumab

Clinical trials

Trials with this intervention (13)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–13 of 13 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01587040	Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen	completed	Phase 1 / Phase 2	61	SanofiINDUSTRY	4	Apr 19, 2022	clinicaltrials
NCT01013324	Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma	completed	Phase 2	67